Wishing you continued health, wellness, and great results on your journey with OZiva
Impact on the research peptide market FDA approval will fundamentally change the online retatrutide market
(A and B) Immunoblotting assays showing shCD36 reverses BRD4 and AR degradation by SIM1-Me (A) and ARV-110 (B), respectively, in LNCaP cells under indicated conditions.(E and F) Immunoblotting assays showing increasing expression of HA-tagged CD36 protein in shCD36-LNCaP cells restores BRD4 and AR degradation by SIM1-Me (E) and ARV-110 (F), respectively, in LNCaP cells under indicated conditions.(GJ) Viability of shEEA1+Vec-, shLuc+Vec-, shCD36+Vec-, shCD36+CD36-LNCaP cells determined by MTT assays after incubation with increasing concentrations of SIM1-Me (G), ARV-110 (H), MZ1 (I), or paclitaxel (J)
The rationale is receptor pathway complementaritysince they target different receptors, co-administration may produce synergistic effects without receptor competition